Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
Alzheimer’s disease (AD) is the most widespread form of dementia, affecting about 45 million people worldwide. Although the β-amyloid peptide (Aβ) remains the most acknowledged culprit of AD, the multiple failures of Aβ-centric therapies call for alternative therapeutic approaches. Conceivably, the...
Main Authors: | Claudia Balducci, Gianluigi Forloni |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00738/full |
Similar Items
-
Brain injury, neuroinflammation and Alzheimer’s disease
by: Joshua eBreunig, et al.
Published: (2013-07-01) -
Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
by: Xue Meng, et al.
Published: (2019-10-01) -
Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
by: Audrey Hector, et al.
Published: (2021-01-01) -
Amyloid-β Oligomers Unveil a Novel Primate Model of Sporadic Alzheimer’s Disease
by: Joseph eJebelli, et al.
Published: (2015-03-01) -
β-amyloid oligomers in aging and Alzheimer's disease
by: Kathleen R. Zahs, et al.
Published: (2013-07-01)